Table 2 Assessment of efficacy in patients received radical resection

From: Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study

Time from the end of radiotherapy to surgery [median (range)] days

61 (43–84)

R0 resection (yes/no)

46 (100.0%) / 0 (0.0%)

Anal-preserving (yes/no)

41 (89.1%) / 5 (10.9%)

 Defunctioning ileostomy

13 (28.3%)

 Colostomy

5 (10.9%)

 No stomas

28 (60.9%)

AJCC tumor regression grade (0/1/2/3)

20 (43.5%) / 15 (32.6%) / 9 (19.6%) / 2 (4.3%)

ypT category (ypT0/ypT1/ypT2/ypT3/ypT4)

21 (45.7%) / 4 (8.7%) / 4 (8.7%) / 16 (34.8%) / 1 (2.2%)

ypN category (ypN0/ypN1/ypN2)

41 (89.1%) / 4 (8.7%) / 1 (2.2%)

MRI tumor regression grade (0/1/2/3)

18 (39.1%) / 22 (47.8%) / 5 (10.9) / 1 (2.2%)

ycT category (ycT0/ycT1/ycT2/ycT3/ycT4)

18 (39.1%) / 5 (10.9) / 7 (15.2%) / 14 (30.4%) / 2 (4.3%)

ycN category (ycN0/ycN1/ycN2)

40 (87.0%) / 4 (8.7%) / 2 (4.3%)

Clinical evaluation through RECIST

 

CR

18 (39.1%)

PR

18 (39.1%)

SD

10 (21.7%)

PD

0 (0%)

ORR

35 (76.1%)

Neoadjuvant rectal score [median (range)]

14.98 (0.94–70.34)

  1. AJCC American Joint Committee on Cancer, MRI magnetic resonance imaging, RECIST Response Evaluation Criteria in Solid Tumors, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate
Back to article page